Dr Reddys Labs gains 2% on Finasteride launch in US

Healthcare firm Dr Reddy's Laboratories was the top gainer on the Sensex, rising more than 2 percent on Thursday after the company launched Finasteride tablets (1 mg), a bioequivalent generic version of Propecia in the US market.

The company's ANDA for Finasteride tablets has been awarded a 180-day period of marketing exclusivity in the US on January 2.

"The Propecia tablets has US sales of approximately USD 136 million MAT for the most recent 12 months ending October 2012, according to IMS Health," the company said in a release.

At 10:36 hours IST, the stock gained 2.13 percent to Rs 1,877 on the Bombay Stock Exchange.

Also Read
Geometric surges on acquisition of 3Cap Technologies
Jet Air rises 6% on impending stake sale deal with Etihad

Anda sedang membaca artikel tentang

Dr Reddys Labs gains 2% on Finasteride launch in US

Dengan url

https://olahragakecantikan.blogspot.com/2013/01/dr-reddys-labs-gains-2-on-finasteride.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Dr Reddys Labs gains 2% on Finasteride launch in US

namun jangan lupa untuk meletakkan link

Dr Reddys Labs gains 2% on Finasteride launch in US

sebagai sumbernya